GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Accumulated other comprehensive income (loss)

PHVS (Pharvaris NV) Accumulated other comprehensive income (loss) : $46.57 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Pharvaris NV's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was $46.57 Mil.

Pharvaris NV's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2024 ($40.08 Mil) to Dec. 2024 ($41.73 Mil) and increased from Dec. 2024 ($41.73 Mil) to Mar. 2025 ($46.57 Mil).

Pharvaris NV's annual Accumulated other comprehensive income (loss) increased from Dec. 2022 ($21.41 Mil) to Dec. 2023 ($30.40 Mil) and increased from Dec. 2023 ($30.40 Mil) to Dec. 2024 ($41.73 Mil).

Pharvaris NV Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Pharvaris NV's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Accumulated other comprehensive income (loss) Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial 2.40 11.07 21.41 30.40 41.73

Pharvaris NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.48 34.45 40.08 41.73 46.57

Pharvaris NV Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Pharvaris NV Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharvaris NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
SNDX CRMD SYRE QURE WVE CVAC GERN ELVN ZYME NTLA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
9EN:Germany
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Website
https://www.pharvaris.com
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.